179 related articles for article (PubMed ID: 35399603)
1. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.
Zhang Y; Qian L; Chen K; Gu S; Wang J; Meng Z; Li Y; Wang P
Mol Ther Oncolytics; 2022 Jun; 25():31-42. PubMed ID: 35399603
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.
Zhang Y; Qian L; Chen K; Gu S; Meng Z; Wang J; Li Y; Wang P
Mol Ther; 2024 Apr; ():. PubMed ID: 38659226
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus as an agent for the treatment of malignant ascites.
Liu HL; Chen J
Cancer Biother Radiopharm; 2009 Feb; 24(1):99-102. PubMed ID: 19216627
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study.
Wang B; Zhong C; Liao Z; Wang H; Cai X; Zhang Y; Wang J; Wang T; Yao H
Thorac Cancer; 2023 Oct; 14(30):3051-3057. PubMed ID: 37675621
[TBL] [Abstract][Full Text] [Related]
5. The antitumor effects of oncolytic adenovirus H101 against lung cancer.
Lei J; Li QH; Yang JL; Liu F; Wang L; Xu WM; Zhao WX
Int J Oncol; 2015 Aug; 47(2):555-62. PubMed ID: 26081001
[TBL] [Abstract][Full Text] [Related]
6. A novel oncolytic virus induces a regional cytokine storm and safely eliminates malignant ascites of colon cancer.
Dong S; Liu B; Hu S; Guo F; Zhong Y; Cai Q; Zhang S; Qian Y; Wang J; Zhou F
Cancer Med; 2022 Nov; 11(22):4297-4309. PubMed ID: 35510373
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Adenovirus H101 Synergizes with Radiation in Cervical Cancer Cells.
Duan Y; Bai H; Li X; Wang D; Wang Y; Cao M; Zhang N; Chen H; Wang Y
Curr Cancer Drug Targets; 2021; 21(7):619-630. PubMed ID: 33687882
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma
Ma J; Li N; Zhao J; Lu J; Ma Y; Zhu Q; Dong Z; Liu K; Ming L
Oncol Lett; 2017 Jun; 13(6):4868-4874. PubMed ID: 28599488
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study.
Zhang J; Zhang Q; Liu Z; Wang J; Shi F; Su J; Wang T; Wang F
Front Oncol; 2022; 12():877155. PubMed ID: 35574359
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
[TBL] [Abstract][Full Text] [Related]
13. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
14. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
Kuryk L; Møller AW; Garofalo M; Cerullo V; Pesonen S; Alemany R; Jaderberg M
J Med Virol; 2018 Oct; 90(10):1669-1673. PubMed ID: 29797583
[TBL] [Abstract][Full Text] [Related]
15. [Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer].
Xu RH; Yuan ZY; Guan ZZ; Cao Y; Wang HQ; Hu XH; Feng JF; Zhang Y; Li F; Chen ZT; Wang JJ; Huang JJ; Zhou QH; Song ST
Ai Zheng; 2003 Dec; 22(12):1307-10. PubMed ID: 14693057
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.
Gao P; Ding G; Wang L
Transl Cancer Res; 2021 Oct; 10(10):4290-4302. PubMed ID: 35116288
[TBL] [Abstract][Full Text] [Related]
17. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.
Huang X; Jia R; Zhao X; Liu B; Wang H; Wang J; Zhou Y; Cun B; Ge S; Fan X
Br J Ophthalmol; 2012 Oct; 96(10):1331-8. PubMed ID: 22843987
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Manyam M; Stephens AJ; Kennard JA; LeBlanc J; Ahmad S; Kendrick JE; Holloway RW
Gynecol Oncol; 2021 Dec; 163(3):481-489. PubMed ID: 34686353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
